Key statistics
As of last trade Royalty Pharma PLC (RPD:FRA) traded at 25.03, 6.78% above its 52-week low of 23.44, set on Jul 08, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 25.27 |
---|---|
High | 25.27 |
Low | 25.03 |
Bid | 24.94 |
Offer | 25.58 |
Previous close | 25.01 |
Average volume | 593.44 |
---|---|
Shares outstanding | 593.46m |
Free float | 384.69m |
P/E (TTM) | 18.76 |
Market cap | 16.74bn USD |
EPS (TTM) | 1.50 USD |
Annual div (ADY) | 0.7617 EUR |
---|---|
Annual div yield (ADY) | 3.05% |
Div ex-date | Aug 16 2024 |
Div pay-date | Sep 13 2024 |
Data delayed at least 15 minutes, as of Sep 19 2024 15:07 BST.
More ▼
Announcements
- Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement
- Royalty Pharma to Present at Morgan Stanley’s 22nd Annual Global Healthcare Conference
- Royalty Pharma Reports Second Quarter 2024 Results
- Royalty Pharma Appoints Molly Sawaya as Executive Vice President, Head of Human Capital
- Royalty Pharma to Announce Second Quarter 2024 Financial Results on August 8, 2024
- Royalty Pharma Declares Third Quarter 2024 Dividend
- Royalty Pharma to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
- Royalty Pharma Announces Pricing of $1.5 Billion of Senior Unsecured Notes
- Royalty Pharma and Agios Pharmaceuticals Enter Into Vorasidenib Royalty Agreement for $905 Million
- Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline
More ▼